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Regenerative medicine is an emerging area that will inﬂuence the treatment of joint diseases in the
future. It involves the use of biomaterials, cell therapy, and bioactive factors such as growth factors, drugs
and small molecules, to regenerate damaged tissues. This “year in review” highlights a personal selection
of promising studies published between March 2013 and March 2014 that inform on the direction in
which this ﬁeld is moving.
This multidisciplinary ﬁeld has been very active, with rapid development of new technologies that
emerge from basic sciences such as the possibility to generate pluripotent stem cells without genetic
modiﬁcation and genetic engineering of growth factors to enhance their capacity to induce tissue repair.
The increasing knowledge of the interaction between all tissues in the joint, such as the effect of bone
remodeling and synovial inﬂammation on cartilage repair, will eventually make tissue regeneration in a
compromised joint environment possible.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Approximately 25 years ago, three separate papers were pub-
lished that kicked off the ﬁeld of musculoskeletal regenerative
medicine: Langer and Vacanti published the ﬁrst deﬁnition of Tis-
sue Engineering1; cells isolated from the bone marrow were
demonstrated to have multilineage differentiation potential2; and
the ﬁrst cell transplantations for articular cartilage defects were
performed in humans3. Many papers are being published in the
ﬁeld of stem cell biology, on the application of growth factors and
on the development and application of biomaterials. A search in
PubMed (ncbi.nlm.gov/pubmed/) revealed over 6000 hits in the
past year on regeneration/repair of joint tissues (excluding bone
there are still over 2000 publications) and over 25 new clinical
trials on joint regeneration therapies were registered (clinicaltrials.
gov). This review is a personal selection of articles published be-
tween March 2013 and March 2014 in the ﬁeld of regenerative
medicine which results are or might become important for the
development of treatments to regenerate damaged joint tissues.: G.J.V.M. van Osch, Erasmus
ive Tissue Cells and Repair
Otorhinolaryngology, Room
herlands. Tel: 31-10-7043661.
ternational. Published by Elsevier LThis review is not meant as a complete overview of publications of
the year.
Advances in stem cell biology
To regenerate tissue differentiated cells would be the ﬁrst
choice. However, this will require harvesting of tissue thus creating
a tissue defect and, moreover, the capacity to expand these cells in
order to obtain a sufﬁcient number for clinical applications, is
limited. Mesenchymal Stem Cells (MSCs) from adult tissues are
often the next choice. They are generally obtained from patient's
own bone marrow or adipose tissue but other sources, such as the
umbilical cord, are becoming popular as well. The MSCs however,
are a very heterogeneous population of cells and the variability
between donors is high4,5. In 2012 the Nobel prize for medicinewas
awarded to Shinya Yamanaka for the work on induced pluripotent
stem cells. Yamanaka and colleagues described a way to reprogram
adult somatic cells to pluripotent stem cells by genetically intro-
ducing a set of transcription factors ﬁrst in murine cells (2006)6 and
shortly after in human cells (2007)7. Since then the technology
became more wide spread and its efﬁciency has increased. Apart
from their use in patient-characteristic in vitro models the interest
to use these cells for regenerative medicine applications in patients
has grown. This year two papers were published on the attempt
to eliminate the requirement of genetic modiﬁcation to induce
pluripotency. In the ﬁrst paper Hou et al.8 described the possibilitytd. All rights reserved.
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CHIR, a glycogen synthase kinase 3 inhibitor; 616452, a Trans-
forming Growth Factor-beta inhibitor; Forskolin, a cAMP agonist
and DZNep, an S-adenosyl homocyteine hydrolase inhibitor,
essential for Chemically induced Pluripotent Stem Cells (CiPSCs). In
the second paper, Obokata et al.9 published a very intriguing set of
data on the reprogramming of cells by exposure to sub-lethal
environmental cues. Exposure of CD45þ cells from spleens of 1
week old mice to pH 5.4e5.8 for 30 min followed by 7 days culture,
resulted in expression of Oct4 in the surviving cells, indicating cell
reprogramming. These cells obtained by Stimulus-Triggered
Acquisition of Pluripotency (STAP) showed multilineage differen-
tiation potential and the potency to form teratomas and chimaeric
mice. When cultured in medium with Leukemia IFactor, B27 and
Adrencorticotropic hormone (ACTH), STAP cells have the potential
to proliferate and acquire stem cell-like properties. A few other
physical stimuli also gave this effect such as trituration through
capillary pipettes for 20 min and application of streptolysine for 2 h
to damage the cell membrane. Many groups all over the world are
repeating these experiments to conﬁrm the ﬁndings, demon-
strating the high interest in this technology. Many critical notes
were made in the months following the publication and in July the
authors have retracted the paper. Multiple errors were found that
impair the credibility of the study as a whole. The authors stated
that they are unable to say without doubt whether the STAP stem
cells are real. Ongoing studies in the lead authors' institute should
reveal this and if the data can be replicated the potency of this
method as well as the possible application in adult human cells
should become clear afterwards.
One of the main drawbacks of the use of pluripotent cells for
application in patients is the risk of unwanted tissue formation.
Transdifferentiation of cells from one lineage directly into another
lineage without reverting to the pluripotency state might be a so-
lution. Adult human ﬁbroblasts were transdifferentiated into
chondrocytes by viral transduction with two reprogramming fac-
tors, c-Myc and Kruppel-like factor 4 (Klf4), and a chondrogenic
factor, Sox910. These cells produce cartilage without going through
the pluripotent state and they did not form tumors. However, these
cells had only very limited proliferative capacity. The ﬁeld is still
searching for the best cell sources for each regenerative medicine
applications thereby continuously weighing the importance of cell
availability and donor site morbidity, cell expansion possibilities
and costs and the ability, stability and safety of the cells to perform
the required function.
Advances in the use of growth factors
Growth factors are known for their tissue repair activities.
However, high concentrations are required for application of
growth factors in vivo which causes safety issues and high costs.
Slow release systems and gene transfer techniques to increase
production of growth factors by cells are being applied frequently
in the lab to circumvent these problems. To improve the function of
growth factors, genetic engineering can be used. Last year
Martino.et al.11 engineered growth factors that bind better to the
extra-cellular matrix and thus are active for longer period of time9.
They ﬁrst investigated the ability of a large number of growth
factors to bind to matrix proteins. This demonstrated that Placenta
Growth Factors 2 (PIGF2) had a high afﬁnity for many matrix pro-
teins. Its splice variant PIGF1, which does not have the heparin-
binding sequence that PIGF2 has, had a much lower binding af-
ﬁnity. By genetically fusing the PlGF2 heparin-binding domainwith
other commonly used growth factors such as Bone Morphogenetic
Protein 2 (BMP2), Vascular Endothelial Growth Factor (VEGF) and
Platelet Derived Growth Factor (PDGF), they showed increased skinand bone repair. This was not the only example of engineering
growth factors with improved activity. Introducing BMP2 derived
residues into the Bone Morphogenetic Protein Receptor 1 (BMPR1)
binding region of Growth Differentiation Factor 5 (GDF5) resulted
in a 10-fold increase in binding of GDF5 to BMPR1a thereby
increasing its bone forming capacity12. Since the modiﬁcation was
very small, the angiogenic properties of GDF5 were unaltered thus
combining the positive effects of BMP2 and GDF5 in the newly
engineered growth factor resulting in superior bone formation.
Of great interest for regenerative medicine applications in the
clinical setting is the possible use of Platelet Rich Plasma (PRP),
which contains high concentrations of endogenous growth factors.
The product can easily be made from patient own blood and then
applied with low risk. Initially PRP was shown to stimulate cell
proliferation and extra-cellular matrix production, and now an
increasing number of studies indicate its anti-inﬂammatory ef-
fects13,14. The high number of reviews written on PRP in the last
year indicates its popularity. But although the clinical studies per-
formed so far show promising results, there is still limited evidence
for efﬁcacy because of the lack of high quality studies15.
Advances in the use of biomaterials
Many synthetic and natural materials have been developed and
evaluated as scaffold or carrier of cells and bioactive factors to
stimulate tissue repair. One approach that has become very popular
and appealing for tissue repair is the use of decellularised tissues.
The principle of this technology is to remove the cells and therefore
the antigenicity of the tissue whereas retaining the structural
functionality of the extracellular matrix. The technology has
attention for whole organ replacements such as liver, heart and
lung. The ﬁrst clinical application of decellularised tissue in patients
was actually done with cartilage to successfully replace part of the
airway16. Since then protocols for various types of cartilage are
being optimized to obtain good cell removal but at the same time
preserve as good as possible the structural and mechanical prop-
erties of the tissue. Besides their direct application in surgical re-
constructions, these materials, based on natural, bioactive
components, can be expected be applied in biotechnological pro-
cedures to obtain cells or tissues for tissue engineering procedures.
At themoment cell seeding in thesematerials appears to be a major
challenge.
Inspired by the decellularisation approach, people have started
to produce cell culture derived extracellular matrices in the lab that
can be decellularised to generate a cell-free materials17. These
materials can then be used as scaffold to study the effect of cell-
speciﬁc extracellular matrix on cellular behavior or to in future
possibly also to seed autologous cells for tissue reconstructions.
A very nice example of translational research from development
in the lab towards a level 1 clinical study is BTS-CarGel18. This
mixture of chitosan gel with autologous blood, was investigated for
the treatment of cartilage defects in a multicenter randomized
controlled study involving 26 centers from all over the world. The
study included 39 patients in the BTS-CarGel treatment group and
41 that were treated with conventional microfracture. The primary
outcomemeasurewas blinded evaluation of 3D defect ﬁlling and T2
relaxation on Magnetic Resonance Imaging (MRI) after 12 months.
This demonstrated statistically signiﬁcantly more lesion ﬁlling and
more hyaline cartilage in the BST-CarGel group. Although there
were no difference in clinical improvement of the patients and it
remains to be seen in futurewhether the beneﬁt on the long term is
good enough, the method demonstrated to be safe, affordable and
easy to apply.
This method was optimized from a laboratory setting and basic
research is still being performed to further understand the process,
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rabbits, hyaline cartilage regeneration after microdrilled holes with
chitosan/blood implant was associated with increased remodeling
of the bone19. Bone remodeling processes can affect cartilage, as we
know from osteoarthritis. High levels of TGF-beta (that could be
released either from the macrophages, osteoclasts or from the bone
matrix) can stimulate bone resorption by osteoclasts, as well as
angiogenesis, bone formation by MSCs and chondrogenesis.
Blocking TGF-beta signaling in nestin-positive MSCs in bone was
shown to prevent changes in bone architecture and reduce osteo-
arthritis development after transection of the anterior cruciate
ligament in mice and rats20. So increased subchondral bone
remodeling can be either positive17 or negative20 for the cartilage.
This conﬁrms the importance of understanding the crosstalk be-
tween the bone-cartilage unit. To facilitate studies on the role of
subchondral bone in cartilage repair, an in vitro defect model in
young bovine osteochondral biopsies was developed that showed
that factors secreted by living bone can induce chondrogenic dif-
ferentiation in MSCs21. Knowledge on the inﬂuence of bone on
cartilage regeneration, the role of growth factors and cells and the
effect of compromised bone in joint diseases is of importance to
improve the treatment of cartilage lesions.
Regeneration and (joint) inﬂammation
Whenever we need tissue regeneration, we are dealing with a
compromised environment that will have signs of inﬂammatory
processes. Joint inﬂammation is generally believed to have adverse
effects on cartilage repair. Using mice of different genetic back-
grounds, an inverse relationship was shown between cartilage
healing and susceptibility for posttraumatic osteoarthritis22.
Superhealer Murphy Roths Large (MRL/MpJ) mice that have
demonstrated the capacity to heal articular cartilage23, appeared to
have less inﬂammation than C57Bl6 mice after intra-articular
fracture and their fractures indeed resulted less frequently in
posttraumatic arthritis24. In another study the same group inves-
tigated whether MSCs of MRL mice have better regenerative ca-
pacity than the MSCs of C57Bl6 mice25. Bone marrow derived MSCs
from MRL/MpJ mice appeared to form more colonies but did not
have a better differentiation capacity, which might indicate better
regenerative capacity. Moreover, MSCs from both mouse strains
injected after intra-articular fracture in the knee of the badly
healing C57Bl6 mice, appeared to prevent the development of post-
traumatic arthritis25. Presumably, the injected MSCs caused a mild
increase in anti-inﬂammatory cytokine levels in the synovial ﬂuid.
This anti-inﬂammatory effect of MSCs on joint tissues has been
shown in vitrowith human bone marrow derived MSCs26 as well as
human adipose derived MSCs27, making stem cells still a promising
cell source for the treatment of osteoarthritis. The number of
clinical studies using stem cells beyond the stage of case series is
increasing and dose response safety studies have been conducted28.
However, inﬂammation is not only preventing tissue regenera-
tion. Attraction of more macrophages by the recruitment agent
SEW2871 and PRP hydrogel, lead to more bone regeneration in
rats29. A crucial role for macrophages in tissue regeneration was
also demonstrated in salamanders30. Early after amputation of the
salamander limb, anti-inﬂammatory macrophages appear along
with the pro-inﬂammatory macrophages. Removal of macrophages
using clodronate liposomes prevented limb regeneration. More
knowledge about the dual role of inﬂammation in tissue regener-
ation is required. Targeting the timing of macrophage presence and
macrophage phenotype in mammalian wound healing processes
will probably lead to enhanced outcome of tissue repair opening
new possibilities in the regeneration of tissues in inﬂamed envi-
ronment such as an osteoarthritic joint.Concluding remarks
Fast progression in the ﬁelds of stem cell biology, growth factors
and biomaterials and the improving multidisciplinary relations
between biologists, pathologists, immunologists, engineers and
clinical scientists may in the future offer possibilities to regenerate
joint tissues when prevention of osteoarthritis has failed.Author contribution
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